top of page



SMDG selected for Femtech and Women's Health Programme

SMDG has been selected to participate in the Discovery Park, Spark Femtech and Women's Health cohort programme. This is the first of its kind programme in the UK focusing on companies developing therapies for women's health. This is in recognition of our innovative and pioneering work on neurological diseases and women's health.

May 2024

Drug Delivery Journal.jpg

Dr Moein Moghimi appointed Editor in Chief  

Professor Moein Moghimi, our Co-Founder and inventor of our therapeutic platforms has been appointed the Editor in Chief of the prestigious journal of "Drug Delivery".  A Taylor and Francis Journal, Drug Delivery publishes open access peer-reviewed research on the development and application principles of drug delivery and targeting at molecular, cellular, and higher levels.   Drug Delivery aims to serve both the academic and industrial communities and publishes papers on the following topics:  All drug delivery systems, including oral, pulmonary, nasal, parenteral and transdermal delivery,   All modes of drug entry, such as controlled release systems; Microcapsules, liposomes, vesicles, and macromolecular conjugates,  Antibody targeting, Protein/peptide delivery, DNA, oligonucleotide and siRNA delivery.

April 2024

Dr Zsusanna Devercerci.jpg

SMDG announces appointment of industry leader Dr Zsuzsanna Devecseri to the Board of Directors

SMDG has appointed Dr Zsuzsanna Devecseri, M.D., MBA, to its Board of Directors (Board). Dr. Devecseri is a highly successful biopharmaceutical business executive who brings extensive leadership experience to SMDG as it progresses towards an important critical period of growth. Zsuzsanna Devecseri, MD, MBA, is the Global Head, Medical Affairs, Oncology, Novartis, 

March 2024

smaller image for CEO of the year award.png

Dr Farhangrazi recognised as the CEO of the Year  

Dr Shadi Farhangrazi, our CEO, has been named one of recipients of the  SME News- CEO of the Year Awards.
Most Innovative Life Saving Therapy CEO – UK,  

March 2024


Dr Farhangrazi invited for a Fireside Chat 

Dr. Shadi Farhangrazi, our CEO, has been invited to join a fireside chat with Dr. Angela Cacace and Dr. Katie Digiananitonio from Arvinas, a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics, based in New Haven, Connecticut, USA.  The virtual conversation will be held on March 8th in commemoration of International Women's Day and will be attended by hundreds of Arvinas employees. The discussion will focus on Dr. Farhangrazi's journey as a scientist and woman.  

March 2024

bottom of page